Personalized vs. Fixed-Activity 177Lu-PSMA-617 Radiopharmaceutical Therapy (PRODIGY-2)

This trial is comparing two dosing strategies for lutetium-177 PSMA-617 (a targeted radioactive treatment for prostate cancer) — a fixed dose versus a personalised dose based on each patient's body — to see which approach is safer and more effective. **You may be eligible if...** - You are a man aged 18 or older - You have metastatic castration-resistant prostate cancer (cancer that has spread and continues to grow despite testosterone-lowering treatment) - Your cancer is PSMA-positive on a PET scan - Your PSA level is rising and is at least 2 ng/mL - You have received at least one prior hormone therapy for resistant disease - Your kidney function and blood counts are adequate **You may NOT be eligible if...** - Your cancer has extensive bone-only spread on PSMA PET (so-called "superscan") - You have severe kidney impairment (eGFR below 45) - You have active or progressing brain metastases - You have had prior lutetium-177 PSMA therapy Talk to your doctor to see if this trial is right for you.